Late-Stage COVID-19 Vaccine Trial On Hold

AstraZeneca has paused its COVID-19 vaccine trial after a participant in the UK experienced an adverse reaction. This is the first known suspension of a phase three COVID-19 vaccine trial. Experts note that such pauses are not uncommon and are part of routine safety reviews. The trial, which aims to enroll 30,000 participants in the US, is under scrutiny, and more information is expected soon. A data safety monitoring board will review the trial data to ensure safety. Pharmaceutical companies assure the public that a vaccine will only be introduced once it is safely approved.

What was the reason for AstraZeneca pausing its COVID-19 vaccine trial?

• A new vaccine was developed.

• The trial reached its final phase.

• The vaccine was found to be ineffective.

• A participant experienced an adverse reaction.

Why are pauses in vaccine trials not considered uncommon?

• They are used to gather more participants.

• They indicate the vaccine is ready for approval.

• Participants can fall ill by chance, requiring review.

• They are a sign of trial failure.

How many participants are expected to enroll in the US for AstraZeneca's phase three trial?

• 40,000

• 30,000

• 20,000

• 10,000

What is the role of the data safety monitoring board in the vaccine trial?

• To recruit more participants.

• To review trial data and adverse events.

• To approve the vaccine for public use.

• To manufacture the vaccine.

What have nine pharmaceutical companies pledged regarding the COVID-19 vaccine?

• To release the vaccine as soon as possible.

• To ensure the vaccine is safe before release.

• To stop all vaccine trials.

• To merge their research efforts.